SCHEMBL1617176

SCHEMBL1617176

CN(C)/C=C1\CCCC(c2ccc(Cl)cc2)C1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP1LC3B Q9GZQ8 2/20 0.47
CCR6 P51684 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C1 Q04828 1/20 0.36
SRD5A1 P18405 1/20 0.35
NPC1 O15118 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 3/20 0.34
PBRM1 Q86U86 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRA5 P31644 1/20 0.33
HTR2A P28223 2/20 0.33
HTR2C P28335 2/20 0.33
HTR2B P41595 2/20 0.33
HRH3 Q9Y5N1 2/20 0.33
KDM4E B2RXH2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SLC2A1 P11166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1617177 1.00 MAP1LC3B (0.47) MAP1LC3BCCR6AKR1C3AKR1C1SRD5A1
SCHEMBL1616878 0.86 MAP1LC3B (0.47) MAP1LC3BNPC1ALDH1A1HTR2AHTR2C
SCHEMBL1616876 0.86 MAP1LC3B (0.47) MAP1LC3BNPC1ALDH1A1HTR2AHTR2C
SCHEMBL1617137 0.85 MAP1LC3B (0.44) MAP1LC3BHPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL1615803 0.85 SLC6A2 (0.42) SMN1; SMN2
SCHEMBL1615801 0.85 SLC6A2 (0.42) SMN1; SMN2
SCHEMBL1616933 0.81 GAA (0.39) MAP1LC3BNPC1RAB9AALDH1A1PBRM1
SCHEMBL1616932 0.81 GAA (0.39) MAP1LC3BNPC1RAB9AALDH1A1PBRM1
SCHEMBL1617077 0.78 MAP1LC3B (0.36) MAP1LC3BSRD5A1NPC1RAB9APBRM1
SCHEMBL1617075 0.78 MAP1LC3B (0.36) MAP1LC3BSRD5A1NPC1RAB9APBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012030952-A3 REDUCING RIPPLE CURRENT IN A SWITCHED-MODE POWER CONVERTER EMPLOYING A BRIDGE TOPOLOGY TEXAS INSTRUMENTS INCORPORATED (US) 2012-05-10 WO disclosed
EP-2231629-B1 MODULATORS FOR AMYLOID BETA HOFFMANN LA ROCHE (CH) 2011-11-30 EP disclosed
US-7923450-B2 Modulators for amyloid beta HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
EP-2231629-A1 MODULATORS FOR AMYLOID BETA F. Hoffmann-La Roche AG (CH) 2010-09-29 EP disclosed
WO-2009087127-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 WO disclosed
US-20090181965-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181965-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, BACE1 MAP1LC3B 818/4885CCR6 4624/4885AKR1C3 1824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.